The $250 million milestone payment provides immediate, non-dilutive capital and validates Zymeworks' royalty-aggregation strategy. Traders should watch for Jazz's commercial launch execution and any updates on additional regulatory approvals (e.g., colorectal cancer) that could unlock further milestones. The stock may re-rate as the long-term royalty stream becomes more visible.
Drug in focus
ZYME drug pipeline →Ziihera
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and marketed. First FDA approval was November 2024 (BTC), second was August 2026 (GEA).
- Next catalyst
- None dated
What to watchZiihera is already approved in two indications (BTC and GEA) and generating royalty revenue through partners Jazz and BeOne. The next major catalyst would be a potential regulatory filing for HER2+ colorectal cancer following the August 2026 Breakthrough Therapy Designation, but no PDUFA date has been set. Watch for quarterly royalty revenue growth and any label expansion filings as the key value drivers.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Aug 25 $27.47entry
- T+1 · 3mo ago +6.68%α +6.66% · $29.31
- T+5 · 3mo ago +8.01%α +8.55% · $29.67
- T+20 · 8w ago +0.11%α −0.87% · $27.50
- T+58 · todayOpen
- T+60 · tomorrow Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zymeworks announced that its partner Jazz Pharmaceuticals received FDA approval for two Ziihera (zanidatamab-hrii)-containing regimens for first-line HER2+ gastroesophageal adenocarcinoma (GEA). This approval triggers a $250 million milestone payment to Zymeworks, bringing total upfront and milestone payments from Jazz to $650 million, with up to $1.3 billion in additional milestones and tiered royalties of 10-20% on net sales remaining. This is the second FDA approval for zanidatamab in under two years, significantly de-risking the asset and providing substantial non-dilutive capital to fund Zymeworks' wholly-owned pipeline.
Key Facts
- FDA approved two Ziihera-containing regimens for first-line HER2+ GEA, including with and without tislelizumab plus chemotherapy.
- Zymeworks earned a $250 million milestone payment from Jazz Pharmaceuticals upon this approval.
- Total upfront and milestone payments received from Jazz now total $650 million.
- Zymeworks remains eligible for up to $1.3 billion in additional regulatory and commercial milestones plus tiered royalties of 10% to 20% on Jazz's net sales.
- This is the second FDA approval for zanidatamab in less than two years, following its accelerated approval in biliary tract cancer.
- The approval is supported by Phase 3 HERIZON-GEA-01 trial results published in the New England Journal of Medicine.
- Zymeworks also has a separate collaboration with BeOne Medicines, with $81 million received to date and up to $144 million in additional milestones plus tiered royalties of up to 19.5%.
Financial Impact
$250 million milestone payment triggered immediately, with potential for up to $1.3 billion in additional milestones and tiered royalties of 10-20% on Jazz net sales. Separately, up to $144 million in additional milestones from BeOne plus tiered royalties of up to 19.5%.
Risk Factors
- Continued approval for the biliary tract cancer indication is contingent on confirmatory trial results.
- Commercial success of Ziihera depends on Jazz's sales execution and market adoption.
- Zymeworks remains dependent on partners for development and commercialization, with no control over timelines or outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (ZYME), Batch item 1 | 0001937653-26-000051 |
| Document: 0001937653-26-000051-index.html | 0001937653-26-000051 |
| Document: 0001937653-26-000051.txt | 0001937653-26-000051 |
| 8-K Filing (ZYME), Batch item 4 | 0001937653-26-000051 |
| Document: 0001937653-26-000051-index.html | 0001937653-26-000051 |
| Document: 0001937653-26-000051.txt | 0001937653-26-000051 |
Track record
25 reports on ZYME
5 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +16.72% at T+60 after the Jun 14, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today 8-K Neutral 4/10 Entry price pending
- Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $26.24 Now $26.24 −0.00% settles Dec 14
- Nov 9, 20267d ago 8-K/A Neutral 5/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $30.94 Now $26.24 −15.19% settles Dec 3
- Oct 26, 202621d ago DEFA14A Neutral 2/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
- Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $28.22 Now $26.24 −7.02% settles Nov 20
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $25.75 to $29.07 Now $26.24 +1.90% ▲ +12.89% +14.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers